<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645863</url>
  </required_header>
  <id_info>
    <org_study_id>MT-6548-J05</org_study_id>
    <nct_id>NCT03645863</nct_id>
  </id_info>
  <brief_title>Effects of Iron Supplements on the Pharmacokinetics of MT-6548</brief_title>
  <official_title>A Clinical Pharmacological Study to Evaluate the Effects of Iron Supplements on the Pharmacokinetics of MT-6548 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to investigate the pharmacokinetics and safety of MT-6548
      co-administered with iron supplements in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity(AUC0-∞) of unchanged MT-6548</measure>
    <time_frame>Up to Day 8 (Cohort 1), Up to Day 5 (Cohort 2, 3)</time_frame>
    <description>No primary endpoint is used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of unchanged MT-6548</measure>
    <time_frame>Up to Day 8 (Cohort 1), Up to Day 5 (Cohort 2, 3)</time_frame>
    <description>No primary endpoint is used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration (tmax) of unchanged MT-6548</measure>
    <time_frame>Up to Day 8 (Cohort 1), Up to Day 5 (Cohort 2, 3)</time_frame>
    <description>No primary endpoint is used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero until the last quantifiable concentration (AUC0-last) of unchanged MT-6548</measure>
    <time_frame>Up to Day 8 (Cohort 1), Up to Day 5 (Cohort 2, 3)</time_frame>
    <description>No primary endpoint is used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time from zero to infinity (MRT0-∞) of unchanged MT-6548</measure>
    <time_frame>Up to Day 8 (Cohort 1), Up to Day 5 (Cohort 2, 3)</time_frame>
    <description>No primary endpoint is used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination rate constant (Kel) of unchanged MT-6548</measure>
    <time_frame>Up to Day 8 (Cohort 1), Up to Day 5 (Cohort 2, 3)</time_frame>
    <description>No primary endpoint is used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (t1/2) of unchanged MT-6548</measure>
    <time_frame>Up to Day 8 (Cohort 1), Up to Day 5 (Cohort 2, 3)</time_frame>
    <description>No primary endpoint is used.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive MT-6548 on Day 1, 4, and 7. Subject will receive Iron supplement A on Day 1, 4, or 7. Subject will receive Iron supplement B on Day 1, 4, or 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive MT-6548 on Day 1 and 4. Subject will receive Iron supplement C on Day 1 or 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive MT-6548 on Day 1 and 4. Subject will receive Iron supplement D on Day 1 or 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-6548</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>vadadustat</other_name>
    <other_name>AKB-6548</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron supplement A</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron supplement B</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron supplement C</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron supplement D</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parents and each grandparent of subjects are Japanese

          -  Subjects judged as appropriate for this study by investigators based on the results of
             the tests at Screening, Day -1 and Day 1

        Exclusion Criteria:

          -  Subjects with signs of heart diseases on the result of screening test

          -  Subjects with current conditions or histories of drug addiction or alcohol addiction

          -  Subjects judged by investigators that they cannot comply with the prohibition during
             the confinement period

          -  Subjects who have taken MT-6548 before

          -  Subjects with current conditions or histories of drug or food allergies

          -  Subjects with BMI below18.5 kg/m2, BMI above 25.0 kg/m2 or body weight below 50.0 kg
             at the screening test

          -  Subjects who have undergone platelet or plasma donation 2 weeks prior to the consent

          -  Subjects who have undergone blood donation or blood draw of 400 mL or above within 12
             weeks prior to the consent, or 200 mL or above within 4 weeks prior to the consent

          -  Subjects who have undergone blood donation or blood draw of 800 mL or above within one
             year prior to the consent

          -  Subjects who have undergone surgical operations that can affect gastrointestinal
             absorption of medication (appendectomy and hernioplasty do not meet this exclusion
             criterion)

          -  Subjects with positive results for HBs antigen, syphilis serum reaction, HCV antibody
             or HIV antigen / antibody at the screening test

          -  Subjects who are unwilling to consent to use contraception from the beginning of study
             period to 90 days following the final dose of the study drug

          -  Subjects who have participated in another clinical study and received study drugs
             within 12 weeks prior to consent, or within 5 times the half-life of the study drug
             (whichever is longer)

          -  Subjects who have taken any medications except for the drug used for this clinical
             study within 7 days prior to the first dose of the study drug

          -  Subjects who have had supplements within 7 days prior to the first dose of the study
             drug

          -  Subjects who have had apples, citrus fruits such as grapefruits or any food products
             that contain apples or citrus fruits within 7 days prior to the first dose of the
             study drug

          -  Subjects who have had food products which contain St John's Wort within 2 weeks prior
             to the first dose of the study drug
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>October 24, 2018</last_update_submitted>
  <last_update_submitted_qc>October 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

